PODD

Attention Long-Term Shareholders of Insulet Corporation (NASDAQ: PODD); Navan, Inc. (NASDAQ: NAVN); Via Transportation, Inc. (NYSE: VIA); and ZoomInfo Technologies, Inc. (NASDAQ: GTM): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law probes Insulet (PODD) fiduciary duties amid Omnipod corrections

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Grabar Law Office has launched a shareholder investigation into Insulet (PODD) for alleged fiduciary breaches, coinciding with the company’s Omnipod manufacturing corrections announced in March and May 2026. The probe adds legal risk to PODD near-term sentiment, as investors weigh potential reforms or settlements. The broader legal action landscape around related IPOs could amplify volatility in PODD shares in the coming quarters.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Grabar Law investigates Insulet (PODD) for fiduciary breaches with potential shareholder action.</li><li>Omnipod manufacturing issues prompted March 12 and May 26, 2026 medical device corrections.</li><li>Class-action eligibility windows: pre- Feb 21, 2025 or post- May 26, 2026.</li><li>Grabar Law also targets NAVN, VIA, and GTM in separate shareholder investigations.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Insulet Corporation (PODD)</strong>: Subject of fiduciary-duty investigation; Omnipod corrections may affect safety perception.</li><li><strong>Navan, Inc. (NAVN)</strong>: Grabar Law investigating IPO disclosures; indirect effect on market sentiment.</li><li><strong>Via Transportation, Inc. (VIA)</strong>: Federal securities class action linked to IPO disclosures; potential spillover sentiment.</li><li><strong>ZoomInfo Technologies, Inc. (GTM)</strong>: Securities-fraud suit allegations; broad legal risk backdrop for tech names.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category fits Legal/Corporate Developments; article centers on regulatory and fiduciary investigations affecting multiple public companies, including PODD, with potential implications for governance, disclosures, and stock volatility.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal investigations may trigger near-term PODD price volatility on headlines.</li><li>Omnipod corrections heighten product-safety and regulatory scrutiny that could weigh on sentiment.</li><li>No clear settlement details yet; outcome risk remains substantial.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Insulet PODD is the subject of Grabar Law Office fiduciary-duty investigation.</li><li>March 12, 2026: voluntary Medical Device Correction for Omnipod 5 pods.</li><li>May 26, 2026: MDC for Omnipod 5, Omnipod Dash, and Omnipod Eros.</li><li>Purchase windows for potential class action: before Feb 21, 2025 or after May 26, 2026.</li><li>Globe Newswire issued the release date of July 6, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term PODD downside risk from legal investigations; monitor for resolution within 1–3 quarters.</p>
  </section>
</section>


<article>
  <p><strong>Grabar Law Office has announced investigations on behalf of Insulet Corporation shareholders (NASDAQ: PODD) and Navan, Inc. shareholders (NASDAQ: NAVN), alleging potential breaches of fiduciary duties and misstatements in disclosures related to product safety issues and IPO disclosures.</strong></p>

  <section aria-labelledby="insulet-section">
    <h2 id="insulet-section"><strong>Insulet Corporation Investigation Overview (PODD)</strong></h2>

    <p>Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).</p>

    <p><strong>WHAT IS THIS INVESTIGATION ABOUT?</strong> The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.</p>

    <p><strong>IF YOU INVESTED IN PODD SHARES PRIOR TO FEBRUARY 21, 2025</strong>, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <a href="https://grabarlaw.com/the-latest/insulet-shareholder-investigation/" target="_blank" rel="nofollow"><strong>https://grabarlaw.com/the-latest/insulet-shareholder-investigation/</strong></a>, contact Joshua Grabar at <a href="mailto:jgrabar@grabarlaw.com" target="_blank" rel="nofollow"><strong>jgrabar@grabarlaw.com</strong></a>, or call 267-507-6085. Alternatively, if you purchased Insulet shares between February 21, 2025 and May 26, 2026, you can participate in the class action.</p>

    <p><strong>WHY?</strong> As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ: PODD), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.</p>

    <p>The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction" (the "May 2026 MDC"), this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."</p>

    <p><strong>WHAT CAN YOU DO NOW?</strong> If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you are encouraged to visit <a href="https://grabarlaw.com/the-latest/insulet-shareholder-investigation/" target="_blank" rel="nofollow"><strong>https://grabarlaw.com/the-latest/insulet-shareholder-investigation/</strong></a>, contact Joshua Grabar at <a href="mailto:jgrabar@grabarlaw.com" target="_blank" rel="nofollow"><strong>jgrabar@grabarlaw.com</strong></a>, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Insulet shares between February 21, 2025 and May 26, 2026, you can participate in the class action.</p>

    <p><strong>KEY FACTS</strong></p>
    <ul>
      <li>Company: <strong>Insulet Corporation</strong> (NASDAQ: PODD)</li>
      <li>Investigation focus: fiduciary duties and misstatements</li>
      <li>Relevant dates: prior to <strong>February 21, 2025</strong> vs. <strong>February 21, 2025</strong> to <strong>May 26, 2026</strong></li>
      <li>Key events: <em>March 12, 2026</em> voluntary Medical Device Correction for Omnipod 5 Pods; <em>May 26, 2026</em> May 2026 MDC for Omnipod 5, Omnipod Dash, Omnipod Eros</li>
    </ul>

    <p><strong>IMPACT ON PODD</strong> This investigation highlights potential governance and disclosure concerns surrounding Insulet’s manufacturing controls and product safety, which may affect shareholders and the company’s reputation. For investors, this represents a potential path to reforms or recovery options, at no cost to eligible participants.</p>
  </section>

  <section aria-labelledby="navan-section">
    <h2 id="navan-section"><strong>Navan, Inc. Investigation Details (NAVN)</strong></h2>

    <p><strong>Navan, Inc. (NASDAQ: NAVN)</strong>— Grabar Law Office is investigating whether certain officers and directors of Navan, Inc. breached their fiduciary duties owed to the Company and its shareholders.</p>

    <p><strong>WHAT IS THIS INVESTIGATION ABOUT?</strong> Grabar Law Office is investigating allegations concerning Navan's disclosures, internal reporting systems, oversight practices, and public statements made in connection with the Company’s October 30, 2025 initial public offering (IPO).</p>

    <p>If you are a current Navan Inc. (NASDAQ: NAVN) shareholder who has continuously held Navan shares since on or shortly after the Company’s October 30, 2025 IPO, you are encouraged to visit <a href="https://www.globenewswire.com/Tracker?data=njf39l1c3g8zHHPrawsquTLAz2XX1lsaRDTB0aYgROFPTXi_n7cBoYblN1vfSyeP1sp6JrjeqnQKOZ5HaFDI0q2FQPY8WDszts9ZYY1obN0zuzVfQn3O4LidRMHSS7xBaUs65yadw3akXv2H6m1jrLAs53NZqbMqIKJjahEM3g0DWEGHZgbr0OKP9QGYAF9_ikiPNKr5LjggB46aVQMR4w==" target="_blank" rel="nofollow"><strong>https://grabarlaw.com/the-latest/navan-shareholder-investigation/</strong></a>, contact Joshua H. Grabar at <a href="mailto:jgrabar@grabarlaw.com" target="_blank" rel="nofollow"><strong>jgrabar@grabarlaw.com</strong></a>, or call us at 267-507-6085 to discuss your rights and potential claims. You can pursue claims on behalf of Navan against officers and directors responsible for alleged misconduct and seek corporate governance reforms designed to improve oversight, transparency, disclosure practices, and shareholder value, including a court approved service award at no cost to you whatsoever.</p>

    <p><strong>WHY?</strong> As alleged in a federal securities fraud class action complaint, Navan, Inc. (NASDAQ: NAVN) represented in its IPO materials that it had experienced significant growth in revenue, gross booking volume (GBV), and platform adoption. The Company’s offering documents highlighted strong historical growth metrics and discussed plans to continue expanding customer relationships and platform usage. Navan's October 30, 2025 IPO offering documents allegedly omitted material information concerning the Company's business and financial condition, including that at the time of the IPO, Navan possessed information indicating that revenue growth was decelerating and that the Company would substantially increase sales and marketing spending in order to sustain reported growth metrics. The complaint further alleges that these trends were not adequately disclosed to investors in the Company's registration stat...</p>

    <p>Shareholders who held Navan NAVN shares since the IPO may have rights to pursue claims related to alleged misconduct and governance improvements, with the potential for a court-approved service award at no cost to eligible participants.</p>
  </section>

  <section aria-label="key-takeaways">
    <h3>Key Takeaways for PODD and NAVN Investors</h3>
    <ul>
      <li><strong>Grabar Law Office</strong> is pursuing investigations on behalf of Insulet PODD and Navan NAVN shareholders.</li>
      <li>Investigations focus on potential fiduciary breaches and disclosure issues tied to the <em>October 30, 2025</em> IPOs and related disclosures.</li>
      <li>Shareholders may have options for reforms or recovery depending on eligibility and timing of purchases.</li>
      <li>The inquiries involve specific product safety developments for Insulet's Omnipod line and broader IPO disclosures for Navan.</li>
    </ul>
  </section>
</article>

Grabar Law Office has launched a shareholder investigation into Insulet (PODD) for alleged fiduciary breaches, coinciding with the company’s Omnipod manufacturing corrections announced in March and May 2026. The probe adds legal risk to PODD near-term sentiment, as investors weigh potential reforms or settlements. The broader legal action landscape around related IPOs could amplify volatility in PODD shares in the coming quarters.

attention-long-term-shareholders-of-insulet-corporation-nasdaq-podd-navan-inc-nasdaq-navn-via-transportation-inc-nyse-via-and-zoominfo-technologies-inc-nasdaq-gtm-grabar-law-office-is-investigating-claims-on-your-behalf

Attention Long-Term Shareholders of Insulet Corporation (NASDAQ: PODD); Navan, Inc. (NASDAQ: NAVN); Via Transportation, Inc. (NYSE: VIA); and ZoomInfo Technologies, Inc. (NASDAQ: GTM): Grabar Law Office is Investigating Claims on Your Behalf

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News